LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

LLY

1,008.98

-0.15%↓

JNJ

201.79

-0.2%↓

ABBV

226.23

-1.07%↓

UNH

330.51

-0.85%↓

AZN

90.18

+0.23%↑

Inicio・Lista de Acciones・Allogene Therapeutics Inc

Allogene Therapeutics Inc

Cerrado

SectorSanidad

1.42 -1.39

Comprar Vender

Resumen

Variación precio

24h

Actual

Mínimo

1.41

Máximo

1.44

Métricas clave
By Trading Economics
Ingresos	9.5M -41M
Margen de beneficios	272,450
Empleados	226
EBITDA	19M -38M

Recomendaciones
By TipRanks
Recomendaciones	Compra Fuerte
Estimación a 12 Meses	+541.26% upside

Estadísticas de Mercado
By TradingEconomics
Capitalización Mercado	46M 308M
Apertura anterior	2.81
Cierre anterior	1.42

Noticias sobre sentimiento de mercado

By Acuity

50%

175 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

1.18 / 1.69 Soporte y Resistencia

Allogene Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

7 dic 2025, 23:00 UTC

Adquisiciones, fusiones, absorciones

Brookfield, GIC Agree $4.5 Billion Deal for Australia's National Storage -- Update

5 dic 2025, 21:08 UTC

Adquisiciones, fusiones, absorciones

Meta Platforms Buys AI-Device Maker Limitless

5 dic 2025, 19:39 UTC

Principales Movimientos del Mercado

Parsons' FAA Bid Loss Clouds Outlook After Rocky Year for Contractors

5 dic 2025, 19:17 UTC

Adquisiciones, fusiones, absorciones

Constellation Energy Agrees to Divest Assets to Finalize Calpine Deal

7 dic 2025, 23:42 UTC

Charlas de Mercado

Nikkei May Rise on Weaker Yen -- Market Talk

7 dic 2025, 23:05 UTC

Charlas de Mercado

RBA Set to Remain 'Emphatically' On Hold, Westpac Says -- Market Talk

7 dic 2025, 22:18 UTC

Charlas de Mercado

RBA Set To Conclude Year With Hawkish Message -- Market Talk

6 dic 2025, 16:52 UTC

Adquisiciones, fusiones, absorciones

As Netflix Swoops In to Buy Warner Bros., We Revisit the Studio's Long, Twisted Journey -- Barrons.com

6 dic 2025, 10:30 UTC

Adquisiciones, fusiones, absorciones

Why Netflix Shareholders Aren't Thrilled to Acquire Warner Bros. -- Heard on the Street -- WSJ

6 dic 2025, 02:38 UTC

Adquisiciones, fusiones, absorciones

How a Netflix-Warner Deal Would Change Everything in Hollywood -- Again -- WSJ

5 dic 2025, 21:59 UTC

Adquisiciones, fusiones, absorciones

Netflix's Megadeal Will Need the Trump Administration's Blessing -- Update

5 dic 2025, 21:50 UTC

Charlas de Mercado

Ganancias

Financial Services Roundup: Market Talk

5 dic 2025, 21:50 UTC

Adquisiciones, fusiones, absorciones

The Netflix and Warner Bros. Deal Is Far From a Sure Thing -- Barrons.com

5 dic 2025, 21:36 UTC

Charlas de Mercado

Return of Shipping to Red Sea a Step Closer, Xeneta Says -- Market Talk

5 dic 2025, 21:35 UTC

Adquisiciones, fusiones, absorciones

The Netflix-Warner Bros. Deal Has a Wildcard. How Paramount Could Still Win. -- Barrons.com

5 dic 2025, 21:26 UTC

Adquisiciones, fusiones, absorciones

Warner Bros. Discovery and Netflix Enter Exclusive Deal Negotiations -- 7th Update

5 dic 2025, 21:12 UTC

Charlas de Mercado

Natural Gas Surge 9% This Week on Strong Flow of Exports -- Market Talk

5 dic 2025, 21:03 UTC

Charlas de Mercado

Ganancias

Bank of Montreal Logs Solid Quarter, Though Some Unease Remains -- Market Talk

5 dic 2025, 21:01 UTC

Charlas de Mercado

Oil Caps Positive Week on Geopolitical Turmoil -- Market Talk

5 dic 2025, 20:43 UTC

Adquisiciones, fusiones, absorciones

Limitless CEO Siroker: Will No Longer Sell Pendant to New Customers

5 dic 2025, 20:43 UTC

Adquisiciones, fusiones, absorciones

Limitless CEO Siroker: Existing Pendant Customers to Be Supported for at Least Another Year

5 dic 2025, 20:42 UTC

Adquisiciones, fusiones, absorciones

Limitless CEO Dan Siroker: Limitless Has Been Acquired by Meta >META

5 dic 2025, 20:01 UTC

Adquisiciones, fusiones, absorciones

Netflix Landed a Big Deal. Now it Could Have a Big Fight. -- WSJ

5 dic 2025, 19:44 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

5 dic 2025, 19:44 UTC

Charlas de Mercado

Canada Dollar Gains Nearly 1% on Jobs Data, Rate Outlook -- Market Talk

5 dic 2025, 19:39 UTC

Charlas de Mercado

Silver Climbs to a New Record High -- Market Talk

5 dic 2025, 19:31 UTC

Adquisiciones, fusiones, absorciones

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dic 2025, 18:30 UTC

Charlas de Mercado

Canada Jobless Rate Can Fall More Before Labor Slack Disappears -- Market Talk

5 dic 2025, 18:28 UTC

Adquisiciones, fusiones, absorciones

Netflix Stock Falls. Wall Street Is Worried About Warner Deal's High Price and Debt. -- Barrons.com

5 dic 2025, 18:24 UTC

Adquisiciones, fusiones, absorciones

AMC and IMAX Stocks Drop. Roku Rises. How the Netflix-Warner Bros. Deal Could Shake Up Entertainment. -- Barrons.com

Comparación entre iguales

Cambio de precio

Allogene Therapeutics Inc previsión

Precio Objetivo

By TipRanks

541.26% repunte

Estimación a 12 Meses

Media 9.17 USD 541.26%

Máximo 14 USD

Mínimo 7 USD

De acuerdo con 8 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Allogene Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

8 ratings

Comprar

Mantener

Vender

De acuerdo con 8 analistas que ofrecen calificaciones bursátiles a para Allogene Therapeutics Inc Dist en los últimos 3 meses.

Puntuación técnica

By Trading Central

1.18 / 1.69Soporte y Resistencia

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There is one bearish event.

Sentimiento

By Acuity

175 / 374 Clasificación en Sanidad

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

Acerca de Allogene Therapeutics Inc

Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.